scholarly journals BIRC7 and STC2 Expression Are Associated With Tumorigenesis and Poor Outcome in Extrahepatic Cholangiocarcinoma

2020 ◽  
Vol 19 ◽  
pp. 153303382097167
Author(s):  
Jiequn Li ◽  
Zhulin Yang ◽  
Shengfu Huang ◽  
Daiqiang Li
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Diagnostic And Prognostic Application ◽  
Staining Technique ◽  
Clinicopathological Characteristics ◽  
Extrahepatic Cholangiocarcinoma ◽  
Node Metastasis ◽  
Kaplan Meier ◽  
Potential Biomarker ◽  
Prognostic Application

Background: Extrahepatic cholangiocarcinoma (EHCC) is a highly aggressive epithelial malignancy and has a poor prognosis for the insensitivity to therapies and difficulty in detection. Novel targets and biomarkers are urgently needed to develop for functional, diagnostic and prognostic application on EHCC. Methods: Immunohistochemical staining technique using the EnVision antibody complex was performed on the samples obtained from 100 EHCC, 30 peritumoral extrahepatic biliary tract (EHBT), 10 EHBT adenomas and 15 normal EHBT tissues. Results: The positive rates of BIRC7 and STC2 expression in tissues obtained from peritumoral EHBT, EHBT adenomas and normal EHBT were significantly lower than those in EHCC tissues. BIRC7 and STC2 proteins were expressed at significantly higher levels in patients with lymph node metastasis, invasion of adjacent tissues, and higher TNM stage (III and/or IV) and unable to undergo resection (biopsy only). Kaplan-Meier survival curves indicated that significantly decreased overall survival rate in patients with positive-BIRC7 or positive-STC2 expression compared with patients of negative-BIRC7 or negative-STC2 expression, respectively. Cox-proportional regression analysis demonstrated that positive-BIRC7 and positive-STC2 expression, along with poor differentiation of EHCC, tumor size >3 cm, lymph node metastasis, invasion of adjacent tissues and unable to undergo resection are independent prognostic factors of EHCC patients. Conclusions: The levels of BIRC7 and STC2 expression were correlated with clinicopathological characteristics of EHCC, and positive expression of BIRC7 and STC2 are associated with progression and poor clinical outcomes of EHCC. BIRC7 and STC2 might be a potential biomarker for EHCC in clinic.

scholarly journals BIRC7 and STC2 expression are associated with tumorigenesis and poor outcome in extrahepatic cholangiocarcinoma

2020 ◽  
Author(s):  
Jiequn Li ◽  
Zhulin Yang ◽  
Shengfu Huang ◽  
Daiqiang Li
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Diagnostic And Prognostic Application ◽  
Staining Technique ◽  
Clinicopathological Characteristics ◽  
Extrahepatic Cholangiocarcinoma ◽  
Node Metastasis ◽  
Diagnosis And Prognosis ◽  
Potential Biomarker ◽  
Prognostic Application

Abstract Background: Extrahepatic cholangiocarcinoma (EHCC) is a highly aggressive epithelial malignancy and has a poor prognosis for the insensitivity to therapies and difficulty in detection. Novel targets and biomarkers are urgently needed to develop for functional, diagnostic and prognostic application on EHCC.Methods: Immunohistochemical staining technique using the EnVision antibody complex was performed on the samples obtained from 100 EHCC，30 peritumoral extrahepatic biliary tract (EHBT), 10 EHBT adenomas and 15 normal EHBT tissues.Results: The positive rates of BIRC7 and STC2 expression in tissues obtained from peritumoral EHBT, EHBT adenomas and normal EHBT were significantly lower than those in EHCC tissues. BIRC7 and STC2 proteins were expressed at significantly higher levels in patients with lymph node metastasis, invasion of adjacent tissues, and higher TNM stage (III and/or IV) and unable to undergo resection (biopsy only). Kaplan-Meier survival curves indicated that significantly decreased overall survival rate in patients with positive-BIRC7 or positive-STC2 expression compared with patients of negative-BIRC7 or negative-STC2 expression, respectively. Cox-proportional regression analysis demonstrated that positive-BIRC7 and positive-STC2 expression, along with poor differentiation of EHCC, tumor size >3cm, lymph node metastasis, invasion of adjacent tissues and unable to undergo resection are independent prognostic factors of EHCC patients.Conclusions：The levels of BIRC7 and STC2 expression were correlated with clinicopathological characteristics of EHCC, and positive expression of BIRC7 and STC2 are associated with progression and poor clinical outcomes of EHCC. BIRC7 and STC2 might be a potential biomarker for EHCC diagnosis and prognosis.

scholarly journals BIRC7 and STC2 expression is associated with tumorigenesis and poor outcome in extrahepatic cholangiocarcinoma

2020 ◽  
Author(s):  
Jiequn Li ◽  
Zhulin Yang ◽  
Shengfu Huang ◽  
Daiqiang Li
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Biliary Tract ◽  
Poor Prognosis ◽  
Diagnostic And Prognostic Application ◽  
Tumor Biomarker ◽  
Extrahepatic Cholangiocarcinoma ◽  
Node Metastasis ◽  
Diagnosis And Prognosis ◽  
Tumorigenesis And Progression

Abstract Background: Extrahepatic cholangiocarcinoma (EHCC) is a highly aggressive epithelial malignancy and has a poor prognosis for their insensitivity to therapies and difficulty in detection. Novel targets and biomarkers are urgently needed to develop for functional, diagnostic and prognostic application on EHCC. Methods: 100 EHCC tissues，30 peritumoral tissues, 10 adenoma and 15 normal biliary tract tissues were assayed using EnVision immunohistochemistry. Results: The expression of BIRC7 and STC2 proteins were higher in EHCC tissues than those in peritumoral tissues, adenoma and normal biliary tract tissues. The positive rates of BIRC7 and STC2 expression were significantly higher in cases with lymph node metastasis, invasion to surrounding tissues/organs, and TNM stage III and/or IV and unable to undergo resection (biopsy only). Kaplan-Meier survival curves demonstrated that the overall survival of positive-BIRC7 or positive-STC2 patients was significantly lower than those of negative-BIRC7 or negative-STC2, respectively. Cox-proportional regression analysis demonstrated that positive-BIRC7 and positive-STC2 expression, along with poor differentiation of EHCC, tumor size >3cm, lymph node metastasis, invasion to surrounding tissues/organs and unable to undergo resection are independent prognostic factors of EHCC patients. Conclusions: BIRC7 and STC2 are involved in the tumorigenesis and progression of EHCC, and positive expression of BIRC7 and STC2 are associated with poor prognosis in patients with EHCC. BIRC7 and STC2 might be a potential tumor biomarker for EHCC diagnosis and prognosis.

scholarly journals miR-21 Is a Promising Novel Biomarker for Lymph Node Metastasis in Patients with Gastric Cancer

2012 ◽  
Vol 2012 ◽  
pp. 1-5 ◽  
Author(s):  
Yuejuan Xu ◽  
Jue Sun ◽  
Jianhua Xu ◽  
Qi Li ◽  
Yuewu Guo ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Malignant Disease ◽  
Close Association ◽  
Survival Rates ◽  
Expression Level ◽  
Human Gastric Cancer ◽  
Node Metastasis ◽  
Kaplan Meier

Background. Gastric cancer (GC) is an important malignant disease around the world. Abnormalities of microRNAs (miRNAs) have been implicated in carcinogenesis of various cancers. In the present study, we examined miR-21 expression in human gastric cancer with lymph node metastasis and attempted to uncover its relationship with clinicopathologic data, especially with lymph node metastasis.Materials and Methods. The expression levels of miR-21 in the tumor specimens of GC patients were quantified by RT-PCR. The correlation between miR-21 level and multiple clinicopathological factors was then examined by Mann-Whitney test, Kaplan-Meier survival analysis, and operating characteristic (ROC) analysis.Results. The expression level of miR-21 was higher in GC patients with lymph node metastasis than in those without lymph node metastasis (P<0.05). Expression level of miR-21 was significantly correlated with histologic type, T stage, lymph node metastasis and pTNM stage. The overall survival rates in GC patients with low upregulated miR-21 expression were significantly higher than those with high upregulated miR-21 (P<0.05).Conclusion. A close association is implicated between the elevated miR-21and lymph node metastasis, which could potentially be exploited as a practical biomarker for lymph node metastasis in patients with GC.

scholarly journals β-Catenin Expression Negatively Correlates with WIF1 and Predicts Poor Clinical Outcomes in Patients with Cervical Cancer

2016 ◽  
Vol 2016 ◽  
pp. 1-9 ◽  
Author(s):  
Jinxiao Liang ◽  
Hui Zhou ◽  
Yongpai Peng ◽  
Xiaofei Xie ◽  
Ruixin Li ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Disease Free Survival ◽  
Intraepithelial Neoplasia ◽  
Clinicopathological Characteristics ◽  
Poor Prognostic Factor ◽  
Node Metastasis ◽  
Canonical Wnt ◽  
Wnt Inhibitory Factor 1

Aberrant activation of the canonical Wnt pathway plays a significant role in cervical cancer (CC). However, limited data show the correlation between the cancer clinicopathological characteristics and the key molecules such as β-catenin and Wnt inhibitory factor 1 (WIF1). In this study, β-catenin and WIF1 expression were analyzed by immunohistochemistry for 196 patients with CC, 39 with cervical intraepithelial neoplasia (CIN), and 41 with normal cervical epithelium (NCE). Significant overexpression of β-catenin was detected in CC (67.9%) when compared to CIN (43.6%) or NCE (34.1%), p<0.01, while low WIF1 expression was detected in CC (24.0%) when compared to CIN (59.0%) or NCE (58.5%), p<0.001. Negative correlation was shown between β-catenin and WIF1 expression (r=-0.637, p<0.001). In addition, multivariate analysis revealed that both lymph node metastasis and β-catenin expression were the independent prognostic factors not only for disease-free survival (HR = 5.029, p<0.001; HR = 2.588, p=0.035, resp.), but also for overall survival (HR = 5.058, p<0.001; HR = 2.873, p=0.031, resp.). Our findings indicate that, besides lymph node metastasis, β-catenin expression may also be a poor prognostic factor for CC while WIF1 could be a potential drug target for treatment of advanced CC.

scholarly journals Clinicopathological Characteristics of Lung Adenocarcinoma with Unexpected Lymph Node Metastasis

2017 ◽  
Vol 23 (4) ◽  
pp. 181-187 ◽  
Author(s):  
Tomohiro Haruki ◽  
Makoto Wakahara ◽  
Yuki Matsuoka ◽  
Ken Miwa ◽  
Kunio Araki ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Lung Adenocarcinoma ◽  
Clinicopathological Characteristics ◽  
Node Metastasis

scholarly journals The Clinical and Pathological Significance of Nectin-2 and DDX3 Expression in Pancreatic Ductal Adenocarcinomas

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Shan Liang ◽  
Zhulin Yang ◽  
Daiqiang Li ◽  
Xiongying Miao ◽  
Leping Yang ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Poor Prognosis ◽  
Genetic Basis ◽  
Malignant Disease ◽  
Tnm Stage ◽  
Ductal Adenocarcinoma ◽  
Node Metastasis ◽  
Kaplan Meier ◽  
Poor Differentiation

Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant disease, but the genetic basis of PDAC is still unclear. In this study, Nectin-2 and DDX3 expression in 106 PDAC, 35 peritumoral tissues, 55 benign pancreatic lesions, and 13 normal pancreatic tissues were measured by immunohistochemical methods. Results showed that the percentage of positive Nectin-2 and DDX3 expression was significantly higher in PDAC tumors than in peritumoral tissues, benign pancreatic tissues, and normal pancreatic tissues (P<0.01). The percentage of cases with positive Nectin-2 and DDX3 expression was significantly lower in PDAC patients without lymph node metastasis and invasion and having TNM stage I/II disease than in patients with lymph node metastasis, invasion, and TNM stage III/IV disease (P<0.05orP<0.01). Positive DDX3 expression is associated with poor differentiation of PDAC. Kaplan-Meier survival analysis showed that positive Nectin-2 and DDX3 expression were significantly associated with survival in PDAC patients (P<0.001). Cox multivariate analysis revealed that positive Nectin-2 and DDX3 expression were independent poor prognosis factors in PDAC patients. In conclusion, positive Nectin-2 and DDX3 expression are associated with the progression and poor prognosis in PDAC patients.

scholarly journals Overexpression of 14-3-3δ Predicts Poor Prognosis in Extrahepatic Cholangiocarcinoma Patients

2020 ◽  
Vol 2020 ◽  
pp. 1-6
Author(s):  
Qiao Wu ◽  
Hua Fan ◽  
Ren Lang ◽  
Xianliang Li ◽  
Xingmao Zhang ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Cpg Islands ◽  
Tumor Stage ◽  
Serum Markers ◽  
Extrahepatic Cholangiocarcinoma ◽  
Node Metastasis ◽  
Ca 242 ◽  
A Cell

The protein 14-3-3δ interacts with Trp53 to maintain G2 arrest and thus regulates the cell cycle. Though dysfunction of 14-3-3δ caused by hyper-methylation of CpG islands was reported in several carcinomas, the exact role of this protein in the development of extrahepatic cholangiocarcinoma has not been fully elucidated. Here, we aim at investigating the clinical relevance between 14-3-3δ and human extrahepatic cholangiocarcinoma. We collected extrahepatic cholangiocarcinoma specimens of 65 patients in Beijing Chao Yang Hospital and evaluated their 14-3-3δ expression using immunohistochemistry. We categorized the patients into different subgroups according to clinic pathological factors, such as sex, age, tumor size, pathological classification, lymph node metastasis status, tumor stage, and serum markers including CEA, CA-242, or CA19-9, and further evaluated the correlation between 14-3-3δ expression and these potential prognostic factors. As a result, we detected 14-3-3δ expression in 53 out of 65 specimens (81.5%), and the expression was positively correlated with TNM stage, lymph node metastasis, and overall survival. Our results suggest that 14-3-3δ serves as an oncogenic driver in extrahepatic cholangiocarcinoma tumorigenesis rather than a cell cycle regulator; the overexpression of 14-3-3δ might be frequently acquired by tumor cells to escape appropriate cell cycle regulation. Thus, 14-3-3δ could be a potential target for extrahepatic cholangiocarcinoma diagnosis and therapy.

Sign in / Sign up

Export Citation Format

Share Document